中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

110 records (took 0.03 seconds)

    DARPin을 포함하는 이중 특이 키메라 단백질
    6.
    发明公开
    DARPin을 포함하는 이중 특이 키메라 단백질 审中-实审
    具有DARPins的双特异性嵌合蛋白

    公开(公告)号：KR1020150013084A

    公开(公告)日：2015-02-04

    申请号：KR1020140095090

    申请日：2014-07-25

    Applicant: 삼성전자주식회사

    Inventor： 정광호 ,  이승현 ,  고영준 ,  김민경 ,  황재웅 ,  조미영 ,  이정욱 ,  린포웨이

    IPC: C07K16/46 ,  C07K19/00 ,  A61K39/395

    CPC classification number: C07K16/2863 ,  C07K14/705 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/30 ,  C07K2319/33

    Abstract: The present invention relates to a use of manufacturing of a bispecific chimeric protein including DARPin (bispecific antibody zygocyte). The bispecific chimeric protein manufactured by using DARPin has reduced side effects (agonism) and/or has the increased effects. Provided in an embodiment of the present invention is a bispecific chimeric protein which includes (a) DARPin and (b) an antibody (for example, an antibody of an lgG form), an antibody fragment (an antigen-binding fragment, for example an antibody of scFv-Fc form), or a combination of the same. Provided in another embodiment is a method for manufacturing a bispecific chimeric protein which comprises the step of connecting (a) DARPin to (b) an antibody (for example, an antibody of an lgG form), an antibody fragment (for example, an antibody of scFv-Fc form), or a combination of the same.

    Abstract translation: 本发明涉及制备包含DARPin（双特异性抗体合子）的双特异性嵌合蛋白的用途。 通过使用DARPin制造的双特异性嵌合蛋白具有减少的副作用（激动）和/或具有增加的效果。 在本发明的一个实施方案中提供了双特异性嵌合蛋白，其包括（a）DARPin和（b）抗体（例如，IgG型抗体），抗体片段（抗原结合片段，例如 scFv-Fc形式的抗体）或其组合。 在另一个实施方案中提供了一种制备双特异性嵌合蛋白的方法，其包括将（a）DARPin连接到（b）抗体（例如，IgG型抗体），抗体片段（例如抗体 的scFv-Fc形式），或其组合。

    인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
    8.
    发明公开
    인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도 审中-实审
    人类抗原及抗原成分抗C-MET抗体及其用途

    公开(公告)号：KR1020140119964A

    公开(公告)日：2014-10-13

    申请号：KR1020130034889

    申请日：2013-03-29

    Applicant: 삼성전자주식회사

    Inventor： 이승현 ,  김경아 ,  정광호 ,  송호영

    IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00

    CPC classification number: C07K16/2863 ,  C07K16/3023 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to a humanized and affinity-matured anti c-Met antibody and a pharmaceutical composition for preventing and treating cancer comprising the same, and more specifically, to an anti c-Met antibody including a medium chain variable area having an amino acid sequence of one or more medium chain complementarity determinant areas and a light chain variable area having an amino acid sequence of one or more light chain complementarity determinant areas, or to an an antigen binding segment. According to an embodiment, the pharmaceutical composition for preventing and treating cancer comprising the anti-c-Met antibody can prevent and treat cancer effectively.

    Abstract translation: 本发明涉及人源化和亲和力成熟的抗c-Met抗体和用于预防和治疗癌症的药物组合物，更具体地涉及包括具有氨基酸的中链可变区的抗c-Met抗体 一个或多个中链互补决定区的序列，以及具有一个或多个轻链互补决定区的氨基酸序列的轻链可变区或抗原结合区。 根据一个实施方案，用于预防和治疗包含抗c-Met抗体的癌症的药物组合物可以有效地预防和治疗癌症。

    항 ｃ-Ｍｅｔ 항체 및 그의 용도
    9.
    发明公开
    항 ｃ-Ｍｅｔ 항체 및 그의 용도 无效
    抗C-MET抗体及其用途

    公开(公告)号：KR1020130037153A

    公开(公告)日：2013-04-15

    申请号：KR1020120074691

    申请日：2012-07-09

    Applicant: 삼성전자주식회사

    Inventor： 이승현 ,  최윤아 ,  김경아 ,  송호영 ,  정광호

    IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00

    CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

    Abstract: PURPOSE: An anti-c-Met antibody and a pharmaceutical composition containing the same are provided to effectively prevent or treat cancer. CONSTITUTION: An anti-c-Met antibody has the followings: a heavy chain variable region containing a heavy chain complementarity determining regions of CDR-H1 with an amino acid sequence of sequence number 4, CDR-H2 with an amino acid sequence of sequence number 5, and CDR-H3 with an amino acid sequence of sequence number 6; and a light chain variable region containing a light chain complementarity determining regions of CDR-L1 with an amino acid sequence of sequence number 7, CDR-L2 with an amino acid sequence of sequence number 8, and CDR-L3 with an amino acid sequence of sequence number 9.

    Abstract translation: 目的：提供抗c-Met抗体及含有该抗体的药物组合物以有效预防或治疗癌症。 构成：抗c-Met抗体具有以下重链可变区：包含序列号4的氨基酸序列的CDR-H1的重链互补决定区的重链可变区，具有序列号的氨基酸序列的CDR-H2 5和具有序列号6的氨基酸序列的CDR-H3; 和含有序列号7的氨基酸序列的CDR-L1的轻链互补决定区，序列号8的氨基酸序列的CDR-L2和氨基酸序列的CDR-L3的轻链可变区 序列号9。

    힌지부에 인입/인출 안테나가 실장되는 휴대 통신 단말기
    10.
    发明公开
    힌지부에 인입/인출 안테나가 실장되는 휴대 통신 단말기 无效
    移动电话在铰链单元中具有可回缩天线

    公开(公告)号：KR1020080040916A

    公开(公告)日：2008-05-09

    申请号：KR1020060108885

    申请日：2006-11-06

    Applicant: 삼성전자주식회사

    Inventor： 서광수 ,  정광호

    IPC: H04B1/38

    CPC classification number: H04M1/0216 ,  H01Q1/244

    Abstract: A portable communication terminal mounted with a retractable antenna in a hinge unit is provided to enable two hinge units to function as guides of the antenna when the antenna does an inserting or extracting action, thus it is unnecessary to install independent antenna guide devices. An antenna(30) is mounted to pierce through a hinge unit, and is inserted or extracted in a direction of a hinge shaft in the hinge unit. A contact unit(40) electrically connects the antenna with a body housing. The hinge unit comprises as follows. The first hinge unit(20) receives a hinge module(H). The second hinge unit(22) is disposed by being isolated from the first hinge unit along the hinge shaft, and wherein the antenna pierces therethrough. A cap(312) is completely accepted at an edge of a body housing when the antenna is folded, and is always exposed to the outside.

    Abstract translation: 提供了一种在铰链单元中安装有可伸缩天线的便携式通信终端，以便当天线进行插入或提取动作时，两个铰链单元能够用作天线的引导件，因此不需要安装独立的天线导向装置。 安装天线（30）以穿过铰链单元，并且在铰链单元中沿铰链轴的方向插入或抽出天线（30）。 接触单元（40）将天线与主体外壳电连接。 铰链单元包括如下。 第一铰链单元（20）接收铰链模块（H）。 第二铰链单元（22）通过沿着铰链轴与第一铰链单元隔离设置，并且其中天线穿透其中。 当天线折叠时，帽（312）完全被接纳在主体外壳的边缘处，并且总是暴露于外部。

Patent Agency Ranking